Pharma Two B Completes Enrollment in Phase IIb Study of P2B001 for PD


(March 4, 2015) - Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. "Pharma Two B's P2B001 synergistically combines two non-Levodopa drugs already individually approved for the treatment of the early stages of Parkinson's disease…Our preclinical studies indicate that due to their strong synergy, a low dose combination of these two drugs leads to a significant therapeutic effect, which is further enhanced when these drugs are administered in an adapted release profile enabling them to work in tandem for an extended period of time,” said Pharma Two B CEO Dr. Nurit Livnah. Read more…

Click for a printer friendly version

Back to top